AMGN241206C330000
- 0.01
- 0.000.00%
Amgen Newsroom
'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
Sector Update: Health Care Stocks Decline Premarket Tuesday
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Sector Update: Health Care
Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million
10 Health Care Stocks With Whale Alerts In Today's Session
Amgen, Nike Share Losses Lead Dow's 115-Point Drop
Evercore Maintains Amgen(AMGN.US) With Buy Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN)
Express News | Amgen : Deutsche Bank Cuts Target Price to $285 From $305
AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Amgen Inc. (AMGN): A Bull Case Theory
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ
Boeing, NVIDIA Corp. Share Gains Contribute To Dow's 261-Point Jump
Amgen Inc. (AMGN) Is Attracting Investor Attention: Here Is What You Should Know
Deutsche Bank lowered amgen's target price to $285.
November 29th, Deutsche Bank: lowered Amgen's target price from $305 to $285, maintaining a "hold" rating. (Gelonghui)
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $360
Multiple indications for Beigene's commercialized products have been included in the new version of the national medical insurance pharmaceutical catalog.
Beigene (06160) announced that its self-developed anti-PD-1 antibody drug Bai Ze An (Tislelizumab injection) and the BTK inhibitor Bai Yue Ze (Zerubutinib capsules) have each gained three new indications, and one indication has been included in the national health insurance directory; the product introduced through cooperation with luye pharma, Bai Tuo Wei (Goserelin microspheres for injection), has added one indication that is now included in the national health insurance directory; the product authorized and introduced by Amgen, Kai Luo Si (Carfilzomib for injection), has successfully been renewed. The national health insurance directory will formally implement from January 1, 2025. The company's products Bai Ze An and Bai Yue Ze.